NCT07010107RecruitingPhase 3
Efficacy and Safety of Anaprazole in the Treatment of Reflux Esophagitis: A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Positive-Controlled Phase III Clinical Trial.
Xuanzhu Biopharmaceutical Co., Ltd.1 site in 1 country500 target enrollmentStarted: July 30, 2025Last updated:
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- The endoscopic healing rate of reflux esophagitis
Study Overview
Brief Summary
This Phase III clinical trial is designed to assess the efficacy and safety of Anaprazole 60 mg once daily (QD) administered over a period of up to 8 weeks, compared with Rabeprazole 20 mg QD, in patients with reflux esophagitis.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The patients provided voluntary signed informed consent forms.
- •Aged ≥18 years and ≤75 years old.
- •Endoscopically diagnosed as reflux esophagitis (LA grade B-D) within 14 days before randomization.
Exclusion Criteria
- •Researchers believe that patients with uncontrolled primary diseases are not suitable for clinical trials, particularly those with a history of severe conditions affecting the cardiovascular, nervous, respiratory, hepatic, renal, or other systems.
- •Patients with concomitant diseases that may affect the esophagus or esophageal motility and, could potentially influence the efficacy evaluation.
- •Patients with a history of prior surgical procedures that could potentially impact esophageal function, or surgeries.
- •Patients confirmed to have active peptic ulcers or active upper/lower gastrointestinal bleeding within the last 30 days via esophagogastroduodenoscopy (EGD).
- •Patients with a history of Zollinger-Ellison syndrome, achalasia of the cardia, secondary esophageal motility disorders, irritable bowel syndrome, inflammatory bowel disease, or other gastrointestinal functional disorders.
- •Patients with a history of malignant tumor or having received treatment for malignant tumor within 5 years prior to randomization.
- •Patients with a history of mental illness or a history of drug or alcohol abuse within 12 months prior to screening.
- •Patients who tested positive for HIV, HBsAg, and/or HCV antibodies during screening.
- •Patients with malignant tumors or a predisposition to malignancy in the stomach or esophagus.
- •Patients with abnormal liver function: AST and/or ALT levels ≥2.0×ULN, and/or total bilirubin (TBIL) levels ≥1.5×ULN.
- •Patients with abnormal renal function: Serum creatinine levels ≥1.5×ULN, blood urea or blood urea nitrogen levels ≥1.5×ULN.
- •Patients with clinically significant ECG abnormalities, including QTc interval prolongation (QTcF ≥450 ms for men and QTcF ≥470 ms for women).
- •Patients with poorly controlled diabetes or hypertension.
- •Patients who were unable to undergo esophagogastroduodenoscopy (EGD).
- •Patients with a known allergy to the components or ingredients of Anaprazole or Rabeprazole.
- •Patients who had used proton pump inhibitors at therapeutic doses within 14 days prior to randomization.
- •Patients who had used therapeutic doses of other drugs for treating acid reflux within 7 days prior to randomization.
- •Patients required to continue receiving non-steroidal anti-inflammatory drugs (NSAIDs), systemic glucocorticoids, or clopidogrel during the trial period.
- •Patients whose assessment may be affected by alcohol, drug, or medication withdrawal during the study.
- •Pregnant or lactating women, as well as patients planning to conceive within 30 days before randomization and up to 6 months following the trial completion.
- •Patients who had participated in other drug clinical trials within 3 months prior to randomization.
- •Patients with other conditions deemed by the researchers as unsuitable for participation in this clinical trial.
Arms & Interventions
Anaprazole
Experimental
Anaprazole 3 tablets (20 mg/tablet) + Rabeprazole placebo 1 tablet (0.16 g/tablet), administered orally 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.
Intervention: Anaprazole + Rabeprazole placebo (Drug)
Rabeprazole
Active Comparator
Rabeprazole 1 tablet (20 mg/tablet) + Anaprazole placebo 3 tablets (0.2 g/tablet), orally administered 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.
Intervention: Rabeprazole + Anaprazole placebo (Drug)
Outcomes
Primary Outcomes
The endoscopic healing rate of reflux esophagitis
Time Frame: Up to 8 weeks
The endoscopic healing rate of reflux esophagitis is defined as the proportion of patients with reflux esophagitis who achieve complete mucosal healing. Complete healing is determined by the absence of mucosal breaks upon endoscopic evaluation post-treatment, and the lesion is classified as normal according to the LA classification.
Secondary Outcomes
- The endoscopic healing rate of reflux esophagitis(Up to 4 weeks)
- Changes in the severity and frequency of heartburn compared to the baseline(Up to 8 weeks)
- Changes in the severity and frequency of reflux compared to the baseline(Up to 8 weeks)
- The rate of improvement in the severity and frequency of heartburn(Up to 8 weeks)
- The rate of improvement in the severity and frequency of reflux(Up to 8 weeks)
- Change from baseline in the Gastroesophageal Reflux Disease Health-Related Quality of Life Questionnaire (GERD-HRQL) score(Up to 8 weeks)
- Adverse events(Up to 8 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Aripiprazole in Children and Adolescents With Bipolar I DisorderBipolar DisorderNCT00110461Otsuka Pharmaceutical Development & Commercialization, Inc.296
Completed
Phase 3
Study of Aripiprazole in Patients With Acute Bipolar ManiaBipolar DisorderNCT00097266Otsuka Pharmaceutical Development & Commercialization, Inc.615
Terminated
Phase 4
Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal RefluxLaryngopharyngeal RefluxNCT00369265American Institute for Voice and Ear Research18
Not yet recruiting
Not Applicable
To study therapeutic efficacy of aripiprazole augmentation in treatment resistant obsessive compulsive disorderCTRI/2021/04/032524GMC medical college
Completed
Phase 3
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum DisorderIrritability Associated With Autism Spectrum Disorder (ASD)NCT04174365Otsuka Pharmaceutical Development & Commercialization, Inc.119